StageAcquired | Acquired
About Paragon Bioservices
Paragon Bioservices is a CRO-CMO whose focus is biopharmaceuticals including the production and purification of monoclonal antibodies, recombinant proteins, viral vectors and vaccines. The company provides research services, process development, and cGMP manufacturing. Paragon's cGMP space includes microbial and mammalian suites, fill-finish and fully-segregated virus and BSL-3 facilities.
Missing: Paragon Bioservices's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Paragon Bioservices's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Paragon Bioservices News
Jan 5, 2023
Tyler Patchen News Reporter Sarepta spent much of last year marching forward with its candidate SRP-9001, a gene therapy treatment for the rare but fatal Duchenne muscular dystrophy, eventually filing a BLA for an accelerated approval, with a May 29 PDUFA date and a likely adcomm on the way too. The Cambridge, MA-based biotech on Thursday signed a commercial supply agreement with the New Jersey-based CDMO Catalent to manufacture SRP-9001 and to support other gene therapy candidates in Sarepta’s pipeline for another rare, genetic disease related to muscle deterioration, known as limb-girdle muscular dystrophy (LGMD). Financial details of the deal were not disclosed and Endpoints News did not hear back from Catalent by press time. “Our partnership with the Sarepta team spans nearly a decade across multiple programs and modalities, and we look forward to working together to manufacture these potentially life-changing and life-saving products for patients diagnosed with DMD and LGMD,” said Alessandro Maselli, Catalent’s CEO in a statement . Catalent maintains several gene therapy manufacturing sites, including two in Maryland, outside of Baltimore, and one in Belgium. Sarepta originally settled on a long-term manufacturing agreement with Paragon Bioservices in 2018, but a year later, Catalent acquired Paragon for $1.2 Billion. Alessandro Maselli In 2019, Sarepta inked a $1.15 billion deal with Roche for the rights to the therapy outside the United States, while Sarepta held on to the US rights. In early 2021, SRP-9001 failed in an initial Phase II study, which Sarepta attributed to differences in baseline measures between the older children of the placebo and treatment groups. That fail cut the biotech’s stock in half. However, in the second part of that Phase II study, 20 patients who had received the placebo treatment crossed over to get Sarepta’s gene therapy, the patients showed statistically significant improvements in the motor abilities test that was also used in Part 1. John Carroll Editor & Founder Moderna CEO Stéphane Bancel made it clear early on in their M&A mapping phase that the biotech would be hunting the world for just the right mRNA-related deals to build the company into a global powerhouse. And nothing illustrates that strategy better than the $85 million tuck-in that the biotech is unveiling this morning. Bancel has struck a deal to buy Tokyo-based OriCiro Genomics and its work on cell-free synthesis and amplification of plasmid DNA, building up their set of tech for manufacturing aimed at scaling up production faster and carving weeks out of the process. Keep reading Endpoints with a free subscription Unlock this story instantly and join 154,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP News Reporter A month after the FDA rejected its neuroblastoma drug, the biotech Y-mabs said it will cut 35% of its workforce to save cash and focus on commercializing its lone approved product, Danyelza. The FDA rejected its drug omburtamab on Dec. 2, based on questions about the company’s clinical trial and after an advisory committee voted 16-0 against recommending the drug. The cuts will reduce operating expenses by 28%, and give Y-mabs enough cash to get through the first quarter of 2026. Keep reading Endpoints with a free subscription Unlock this story instantly and join 154,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Paul Schloesser Associate Editor Amgen started off the new year with a bang, joining forces with ADC player Synaffix and agreeing to dole out as high as $2 billion in Synaffix’s largest ADC licensing deal to date. The Dutch biotech — running in the same circles as ADC Therapeutics, Seagen, MacroGenics and Emergence Therapeutics — said Thursday that it secured a licensing deal with Amgen to develop new ADCs. As part of the deal, the Big Pharma gets access to Synaffix’s ADC platforms and technology, starting out with one ADC program. Amgen retains an option to exclusively license four more programs at a later date, but what those programs could be remains under wraps. Read More Beth Snyder Bulik Senior Editor McKinsey Consulting’s Brian Fox is joining Klick Group to boost its commercialization practice. The 18-year McKinsey veteran headed up the commercial life sciences practice there before joining Klick this week in a bid to drive its go-to-market capabilities with clients. Fox’s expertise spans product launches, sales force management, medical and corporate affairs, market access and clinical development. Klick already offers many of those services to biotech and pharma customers, but is looking to Fox to “turbocharge” those efforts, Klick co-founder and chairman Leerom Segal said. Keep reading Endpoints with a free subscription Unlock this story instantly and join 154,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Kyle LaHucik Associate Editor GSK is tapping into WuXi Biologics’ T cell-engaging antibodies in a deal worth as much as $1.5 billion , as the UK drugmaker looks to follow suit of others in the T cell-engager field, which includes Amgen’s marketed cancer drug Blincyto. Only $40 million of the GSK deal will initially go to the Shanghai-based contract research and manufacturing giant, but with a biobuck bet above $1 billion, the Big Pharma sees lots of potential. The pact is a boon to WuXi, which suffered a loss of billions in market value after being placed on the US Department of Commerce’s unverified list last February. WuXi was removed from the list last month. Read More Zachary Brennan Senior Editor Pharma’s annual price increases on drugs — the vast majority of which usually occur in January of every year — didn’t noticeably spike this year (so far) when compared to recent years, and experts say it doesn’t seem like pharma is desperate yet to make up for what may be major losses in sales thanks to government negotiations for some high-earning drugs come 2026. Analysts at 46Brooklyn published their latest 450+ available increases on list prices (not to be confused with the prices people pay out of pocket), as of Jan. 1, finding that as with previous years, most of the increases remained at or below the industry bar of 10%, and a median price increase of 5% so far in 2023. Read More
Paragon Bioservices Frequently Asked Questions (FAQ)
When was Paragon Bioservices founded?
Paragon Bioservices was founded in 1990.
Where is Paragon Bioservices's headquarters?
Paragon Bioservices's headquarters is located at 801 West Baltimore Street, Baltimore.
What is Paragon Bioservices's latest funding round?
Paragon Bioservices's latest funding round is Acquired.
How much did Paragon Bioservices raise?
Paragon Bioservices raised a total of $22.4M.
Who are the investors of Paragon Bioservices?
Investors of Paragon Bioservices include Catalent, Camden Partners and NewSpring Capital.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.